Complera

Antiretroviral Therapy, HIV, HIV + 5 more
Treatment
20 Active Studies for Complera

What is Complera

Tenofovir disoproxilThe Generic name of this drug
Treatment SummaryRilpivirine is a medication used to treat HIV-1 infections in people who have not received prior treatment. It is an NNRTI (non-nucleoside reverse transcriptase inhibitor) drug that works by blocking the action of an enzyme involved in the replication of the virus. It is highly effective and has a low risk of causing resistance compared to other NNRTI drugs. It was approved by the FDA in 2011 and is now available as a two-drug regimen with dolutegravir (Juluca) or cabotegravir (Cabenuva).
Vireadis the brand name
image of different drug pills on a surface
Complera Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Viread
Tenofovir disoproxil
2001
154

Effectiveness

How Complera Affects PatientsRilpivirine is a medication used to treat HIV-1 infection. It can be taken as an oral tablet daily or as an intramuscular injection monthly. Patients should talk to their doctor about the potential risks, such as allergic reactions, liver damage, depression, and changes in body fat.
How Complera works in the bodyRilpivirine is a medicine that works by blocking HIV-1 replication, or the production of new virus cells. It does this by binding to a protein called reverse transcriptase, which is involved in the replication process. This binding stops the production of new virus cells, and helps to prevent the virus from mutating and becoming resistant to treatment.

When to interrupt dosage

The prescribed measure of Complera is contingent upon the recognized condition, such as weight of no less than 35 kg, HIV-1 RNA Not Exceeding 100,000 copies/mL and HIV (Human Immunodeficiency Virus). The amount of dosage is contingent upon the mode of administration (e.g. Tablet, film coated - Oral or Tablet - Oral) as delineated in the table beneath.
Condition
Dosage
Administration
HIV-1 RNA Less Than or Equal to 100,000 copies/mL
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
Antiretroviral Therapy
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
HIV
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
HIV
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
Chronic Hepatitis B Infection
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
virologically-suppressed
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
Obesity
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
Obesity
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral

Warnings

Complera has fifteen counter-indications. It should not be employed in coordination with the conditions given in the following table.There are 20 known major drug interactions with Complera.
Common Complera Drug Interactions
Drug Name
Risk Level
Description
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Tenofovir disoproxil is combined with Neomycin.
Tenofovir
Major
Tenofovir disoproxil may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Tenofovir disoproxil may increase the nephrotoxic activities of Tenofovir alafenamide.
Abacavir
Minor
Tenofovir disoproxil may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetaminophen
Minor
Tenofovir disoproxil may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Complera Toxicity & Overdose RiskIf you have overdosed on this drug, call a poison control center immediately. Those with an overdose should receive supportive treatments and be monitored for changes in their heartbeat. Dialysis is not likely to remove much of the drug from the bloodstream, as it is tightly bound to proteins.

Complera Novel Uses: Which Conditions Have a Clinical Trial Featuring Complera?

43 active clinical trials are currently investigating the potential of Complera to provide therapeutic benefits for individuals with a weight of at least 35 kg, HIV (Human Immunodeficiency Virus) and HIV-1 RNA Levels Less Than or Equal to 100,000 copies/mL.
Condition
Clinical Trials
Trial Phases
Antiretroviral Therapy
1 Actively Recruiting
Phase 2
Obesity
0 Actively Recruiting
HIV-1 RNA Less Than or Equal to 100,000 copies/mL
0 Actively Recruiting
HIV
38 Actively Recruiting
Phase 2, Phase 3, Early Phase 1, Not Applicable, Phase 1, Phase 4
virologically-suppressed
0 Actively Recruiting
Chronic Hepatitis B Infection
6 Actively Recruiting
Phase 3, Phase 2
HIV
0 Actively Recruiting
Obesity
0 Actively Recruiting

Complera Reviews: What are patients saying about Complera?

5Patient Review
4/9/2012
Complera for HIV
I switched to this new medication from another because of the side effects I experienced with the other drug. After only four days on this new medication, I've already noticed vast improvements in my sleep and mood. Additionally, I don't get that "hungover" feeling if I take it a bit later at night.
5Patient Review
4/10/2014
Complera for HIV
Though I've been on this medication for a while now, I recently noticed that my memory has gotten worse and it's hard to concentrate. I'm not sure if it has anything to do with the drug as it's not a very common side effect, but I thought I should mention it.
5Patient Review
12/6/2012
Complera for HIV
I was able to reduce my pill intake from seven per day down to just one thanks to this treatment. My liver enzymes are slightly elevated, but my doctor is monitoring the situation closely. So far, so good!
5Patient Review
7/8/2013
Complera for HIV
I saw a decrease in my viral load from 76294 to 1197 within 30 days. Just be sure you take it with a hearty meal; I experienced some discomfort when I took it on an empty stomach.
5Patient Review
11/11/2013
Complera for HIV
I had some intense gastrointestinal side effects when I first started this treatment, but they eventually subsided. My partner also started the treatment at the same time and didn't experience any problems whatsoever. It's been eight months now and we're both undetectable!
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about complera

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What drugs are in Complera?

"You should ask your healthcare provider if COMPLERA is the right medication for you. COMPLERA is a combination of emtricitabine, rilpivirine, and tenofovir disoproxil fumarate, and it comes in the form of a pill. View the Patient Information leaflet for more information, including important warnings."

Answered by AI

What is Complera used to treat?

"This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life.

This product contains 3 different medications: emtricitabine, rilpivirine, and tenofovir. These medications are used to help control HIV infection by decreasing the amount of HIV in the body. This lowers the individual's chances of developing HIV complications (such as new infections or cancer) and improves quality of life."

Answered by AI

What is the generic name for Complera?

"TENOFOVIR DISOPROXIL FUMARATE is the brand name for tenofovir DF, a nucleotide reverse transcriptase inhibitor.

COMPLERA is a fixed-dose combination tablet containing emtricitabine and rilpivirine hydrochloride, two synthetic nucleoside analogs of cytidine, and tenofovir DF, a nucleotide reverse transcriptase inhibitor."

Answered by AI

Clinical Trials for Complera

Have you considered Complera clinical trials? We made a collection of clinical trials featuring Complera, we think they might fit your search criteria.
Have you considered Complera clinical trials? We made a collection of clinical trials featuring Complera, we think they might fit your search criteria.
Have you considered Complera clinical trials? We made a collection of clinical trials featuring Complera, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top